Equities Research Analysts’ downgrades for Wednesday, October 28th:
Boston Scientific (NYSE:BSX) was downgraded by analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating. They currently have $46.00 price target on the stock.
Datavault AI (NASDAQ:DVLT) was downgraded by analysts at Maxim Group from a buy rating to a hold rating.
Dyne Therapeutics (NASDAQ:DYN) was downgraded by analysts at Oppenheimer from an outperform rating to a market perform rating. The firm currently has $15.00 target price on the stock, down from their previous target price of $40.00.
Enphase Energy (NASDAQ:ENPH) was downgraded by analysts at Oppenheimer from an outperform rating to a market perform rating.
Enphase Energy (NASDAQ:ENPH) was downgraded by analysts at Roth Capital from a buy rating to a neutral rating. The firm currently has $30.00 target price on the stock.
Equinor ASA (NYSE:EQNR) was downgraded by analysts at DZ Bank from a buy rating to a hold rating.
Manulife Financial (TSE:MFC) (NYSE:MFC) was downgraded by analysts at Scotiabank from a sector outperform rating to a sector perform rating. Scotiabank currently has C$67.00 price target on the stock.
Qiagen (NYSE:QGEN) was downgraded by analysts at Barclays from an overweight rating to an equal weight rating. The firm currently has $53.00 price target on the stock, down from their previous price target of $55.00.
Surgery Partners (NASDAQ:SGRY) was downgraded by analysts at UBS Group from a buy rating to a neutral rating. The firm currently has $23.50 target price on the stock, up from their previous target price of $21.00.
Seagate Technology (NASDAQ:STX) was downgraded by analysts at Summit Insights from a buy rating to a hold rating.
Xylem (NYSE:XYL) was downgraded by analysts at JPMorgan Chase & Co. from an overweight rating to a neutral rating. They currently have $90.00 target price on the stock, down from their previous target price of $118.00.
Receive News & Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
